(68)Ga-labeled peptides in tumor imaging

Area of Science:

• Nuclear Oncology
• Radiopharmaceutical Chemistry
• Positron Emission Tomography (PET) Imaging

Background:

• Radiolabeled peptides are gaining importance in nuclear oncology, particularly those using positron emitters.
• Gallium-68 (68Ga) is a key positron emitter due to its availability from in-house generators, eliminating the need for onsite cyclotrons.
• The parent isotope, Germanium-68 (68Ge), has a long half-life, and generator systems effectively prevent its breakthrough in the eluate.

Purpose of the Study:

• To highlight the significance of generator-produced Gallium-68 (68Ga) in nuclear oncology.
• To discuss the development and application of chelator-coupled peptides for 68Ga labeling.
• To explore the potential of these agents in clinical PET imaging.

Main Methods:

• Development of bifunctional chelators, including DOTA and S3N ligands, for efficient 68Ga labeling of peptides.
• Preclinical testing of 68Ga-labeled peptides targeting somatostatin, melanocortin 1, and bombesin receptors.
• Clinical evaluation of 68Ga-labeled peptides, such as 68Ga-DOTA-Tyr3-octreotide, for tumor localization.

Main Results:

• 68Ga-DOTA-Tyr3-octreotide demonstrated higher sensitivity in localizing neuroendocrine tumors compared to 111In-DTPA-octreotide.
• 68Ga-DOTA-based bombesin derivatives show promise in imaging prostate cancer.
• The development of robust generators and chelators facilitates the production of 68Ga-labeled radiopharmaceuticals.

Conclusions:

• Generator-produced 68Ga, combined with small chelator-coupled peptides, heralds a new era of PET radiopharmaceuticals.
• The development of freeze-dried, kit-formulated PET agents is feasible, similar to existing 99mTc-based systems.
• This advancement promises more accessible and versatile PET imaging solutions in nuclear medicine.